References
- Akman, P. (2006), ‘Article 82 reformed? The EC Discussion Paper on exclusionary abuses,’ Journal of Business Law, vol. 816, pp. 821–822.
- Autortiesību un komunicēšanās konsultāciju aģentūra / Latvijas Autoru apvienība v. Concrete padome [2017], C-177/16, EU:C:2017:689.
- Bishop, S. & Walker, M. (2002), The Economics of EC Competition Law: Concepts, Application and Measurement, London: Sweet Maxwell.
- British Leyland plc v. EC Commission [1987], C-226/84, ECLI:EU:C:1986:421.
- Commission Decision of 25 July 2001 relating to a proceeding under Article 82 of the EC Treaty (COMP/C-1/36.915—Deutsche Post AG—Interception of cross-border mail) (Text with EEA relevance) (notified under document number C(2001) 1934), 2001/892/EC, OJ L 331, 15.12.2001.
- Commission Decision of 26 November 2008 relating to a proceeding under Article 82 of the EC Treaty and Article 54 of the EEA Agreement (Cases COMP/39.388— German Electricity Wholesale Market and COMP/39.389—German Electricity Balancing Market) (notified under document number C(2008) 7367 final) (Text with EEA relevance), OJ C 36, 13.2.2009.
- Consolidated version of the Treaty on the Functioning of the European Union, 2012/C 326/01, OJ C 326, 26.10.2012.
- Continental Can v. Commission [1973], C- 6/72, ECLI:EU:C:1973:22.10.1097/00006199-197301000-00012
- Corinne Bodson v. SA Pompes funèbres des régions libérées [1988], C-30/87, ECLI:EU:C:1988:225.
- Decision of the CMA Article 102 TFEU/Chapter II investigation into Pfizer and Flynn Pharma in relation to an alleged abuse of dominance through charging excessive and unfair prices for an anti-epilepsy drug (phenytoin sodium capsules), Case CE/9742-13.
- European Commission (2017), ‘Manufacture of pharmaceutical preparations,’ 40394 Aspen, C.21.2, European Commission Competition Antitrust/Cartel Cases.
- Flynn Pharma Limited, Flynn Pharma Holdings Limited v. Competition and Markets Authority [2018], CAT-11, 1275/1/12/17.
- Fox, E. M. (2002), ‘What is harm to competition? Exclusionary practices and anticompetitive effect,’ Antitrust Law Journal, vol. 70, no. 2, pp. 371–411.
- Incremento prezzi farmaci/Aspen [2016], A480, Autorità Garante della Concorrenza e del Mercato, Bollettino, 36/2016.
- Kanal 5 Ltd and TV4 AB v. STIM [2008], C-52/07, ECLI:EU:C:2008:703.10.1353/imp.2008.0081
- Lyons, B. (2007), The Paradox of the Exclusion of Exploitative Abuse, ESRC Working Paper CCP 08-1. https://doi.org/10.2139/ssrn.108272310.2139/ssrn.1082723
- Manufacture Francaise des Pneumatiques Michelin v. EC Commission [2003], T-203/01, ECLI:EU:T:2003:250.
- Masterfoods Ltd v. HB Ice Cream Ltd. [2000], C-344/98, ECLI:EU:C:2000:689.
- Motta, M. & de Streel, A. (2006), ‘Excessive pricing and price squeeze under EU law,’ in C. D. Ehlermann & I. Atanasiu (eds.) What Is an Abuse of Dominant Position? Portland, OR: Hart Publishing.
- OECD (2011), Working Party No. 2 on Competition and Regulation Excessive Prices, DAF/COMP/WP2/WD (2011)54, 17.10.2011.
- Parke Davis and Co v. Probel, Reese, Beintema-Interpharm and Centrafarm [1968], C-24/67, ECLI:EU:C:1968:11.
- Pfizer Inc. and Pfizer Limited v. Competition and Markets Authority [2017], CMA 1276/1/12/17.
- Röller, H. (2007), `Exploitative abuses,’ ESMT Business Brief No. BB-107-002, p. 5.
- Scandlines Sverige AB v. Port of Helsingborg [2004], COMP/A.36.568/D3.
- Sirena Srl v. Eda Srl and Others [1971], C- 40/70, ECLI:EU:C:1971:18.
- United Brands Company and United Brands Continental BV v. EC Commission [1978], C-27/76, ECLI:EU:C:1978:22.
- Vestager, M. (2016), `Protecting consumers from exploitation,’ Speech held for European Commission at Brussels Chillin’ Competition Conference, 21 November.
- Whish, R. (2009), Competition Law, Oxford: Oxford University Press.